51,700 Shares in Exact Sciences Co. (NASDAQ:EXAS) Acquired by Soros Capital Management LLC

Soros Capital Management LLC purchased a new position in shares of Exact Sciences Co. (NASDAQ:EXAS) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 51,700 shares of the medical research company’s stock, valued at approximately $3,522,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of EXAS. William Blair Investment Management LLC acquired a new stake in shares of Exact Sciences in the second quarter worth $163,896,000. Champlain Investment Partners LLC increased its position in shares of Exact Sciences by 10.9% in the third quarter. Champlain Investment Partners LLC now owns 2,494,480 shares of the medical research company’s stock worth $169,924,000 after acquiring an additional 245,980 shares in the last quarter. Armistice Capital LLC grew its holdings in Exact Sciences by 91.6% during the 2nd quarter. Armistice Capital LLC now owns 1,400,086 shares of the medical research company’s stock valued at $59,154,000 after purchasing an additional 669,438 shares in the last quarter. Principal Financial Group Inc. grew its holdings in Exact Sciences by 19.0% during the 2nd quarter. Principal Financial Group Inc. now owns 1,303,887 shares of the medical research company’s stock valued at $55,089,000 after purchasing an additional 208,641 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in Exact Sciences by 3.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,292,090 shares of the medical research company’s stock valued at $88,017,000 after purchasing an additional 45,015 shares in the last quarter. Institutional investors and hedge funds own 88.82% of the company’s stock.

Insider Buying and Selling at Exact Sciences

In other Exact Sciences news, CEO Kevin T. Conroy bought 19,500 shares of the business’s stock in a transaction that occurred on Wednesday, November 13th. The stock was acquired at an average cost of $51.35 per share, with a total value of $1,001,325.00. Following the completion of the purchase, the chief executive officer now directly owns 1,074,191 shares in the company, valued at approximately $55,159,707.85. This trade represents a 1.85 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, EVP Brian Baranick sold 929 shares of the stock in a transaction that occurred on Tuesday, October 8th. The shares were sold at an average price of $70.00, for a total transaction of $65,030.00. Following the sale, the executive vice president now directly owns 12,758 shares of the company’s stock, valued at approximately $893,060. This represents a 6.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.36% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts have commented on EXAS shares. Jefferies Financial Group increased their price objective on shares of Exact Sciences from $84.00 to $85.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. Stifel Nicolaus reduced their price objective on shares of Exact Sciences from $82.00 to $67.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. BTIG Research increased their price objective on shares of Exact Sciences from $65.00 to $75.00 and gave the company a “buy” rating in a research note on Tuesday. Benchmark reduced their price target on shares of Exact Sciences from $67.00 to $65.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Finally, TD Cowen raised their price target on shares of Exact Sciences from $82.00 to $86.00 and gave the stock a “buy” rating in a research report on Tuesday. One investment analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $75.29.

Exact Sciences Trading Up 9.0 %

EXAS stock opened at $60.10 on Wednesday. The company has a quick ratio of 1.93, a current ratio of 2.12 and a debt-to-equity ratio of 0.72. The firm’s 50-day simple moving average is $64.51 and its 200 day simple moving average is $55.85. Exact Sciences Co. has a fifty-two week low of $40.62 and a fifty-two week high of $79.62.

Exact Sciences (NASDAQ:EXAS) last released its earnings results on Tuesday, November 5th. The medical research company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The company had revenue of $708.66 million for the quarter, compared to analyst estimates of $716.80 million. Exact Sciences had a negative net margin of 7.95% and a negative return on equity of 6.17%. Exact Sciences’s revenue for the quarter was up 12.8% on a year-over-year basis. Analysts predict that Exact Sciences Co. will post -1.13 EPS for the current year.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.